No Data
No Data
No Data
No Data
No Data
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and
GlobeNewswireApr 25 16:30 ET
Ultragenyx Pharma Is Maintained at Buy by TD Cowen
Ultragenyx Pharma Is Maintained at Buy by TD Cowen
Dow JonesApr 24 13:33 ET
Ultragenyx Pharma Price Target Raised to $61.00/Share From $59.00 by TD Cowen
Ultragenyx Pharma Price Target Raised to $61.00/Share From $59.00 by TD Cowen
Dow JonesApr 24 13:33 ET
Express News | Ultragenyx Pharmaceutical Inc : TD Cowen Raises Target Price to $61 From $59
Moomoo 24/7Apr 24 07:24 ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
TipRanksApr 23 08:40 ET
Piper Sandler Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
TipRanksApr 22 08:29 ET
No Data
No Data